RNAC FY 2025 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$218M

FY 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-92.8% YoY

Gross Profit

$00.0% margin

Operating Income

$00.0% margin

Net Income

-$130M-4658.6% margin

EPS (Diluted)

$-5.02

Cash Flow

Operating Cash Flow

-$74M

Free Cash Flow

-$79M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$296M

Total Liabilities

$423M

Stockholders' Equity

-$126M

Cash & Equivalents

$125M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$39M	-92.8%
Gross Profit	$0	$39M	-100.0%
Operating Income	$0	-$44M	+100.0%
Net Income	-$130M	-$77M	-68.3%